Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio ...
A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based ...
The settlement filed in Newark, N.J. federal court comes after similar settlements with Eli Lilly and Sanofi last year. It ...
3d
Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Terence Flynn, Morgan Stanley, inquired about Zepbound payer dynamics and access. Patrik Jonsson explained that Medicare coverage related to obstructive sleep apnea (OSA) is anticipated in the second ...
Eli Lilly and Company (NYSE:LLY – Get Free Report) traded up 0.1% during mid-day trading on Monday after Truist Financial raised their price target on the stock from $1,029.00 to $1,038.00. Truist ...
If California patients pay more than $35 per month for insulin now, it’s in large part because PBMs have rigged the system in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback